Consort Medical plc
Consort Medical plc announces the appointment of Steve Crummett and Ian Nicholson as Non-executive Directors of the Company, effective immediately, and Richard Cotton as Group Finance Director, and as an Executive Director, with effect from 25th June 2012.
Consort Medical plc also announces the retirement of Chris Banks and Jim Dick as Non-executive Directors. They will step down at the Company’s AGM on 30 August 2012. Toby Woolrych, currently Group Finance Director, has decided to leave the Company, and will step down on 29th June 2012, after a handover with his successor.
Chris Banks was appointed as a Non-executive Director in April 2006. He chairs the Audit Committee and is a Member of the Nomination Committee. Jim Dick, who was also appointed as a Non-executive Director in April 2006, chairs the Corporate and Social Responsibility Committee, and is a member of the Remuneration, Audit and Nomination Committees. Toby Woolrych was appointed as Group Finance Director in October 2008.
Steve Crummett is Group Finance Director of Filtrona plc, a FTSE 250 company, having been appointed to the role in 2008. Filtrona is a leading international supplier of speciality plastic, fibre and foam products. From 2003 to 2006, Steve was Group Director, Mergers & Acquisitions of the FTSE 100 company Exel plc. Steve qualified as a Chartered Accountant with Arthur Andersen. He will Chair the Audit Committee, and join the Nomination Committee.
Ian Nicholson has been Chief Executive of Chroma Therapeutics Limited, a drug discovery and development company since 2004. He is Chairman of Bioventix Ltd, a diagnostics company, and a Non-executive Director of Symphogen A/S, an antibody therapeutics company. From 2000 to 2004 Ian was Senior Vice President, Business Development at Celltech Group plc, then the UK’s largest biotechnology company. He has extensive experience in licensing, mergers and acquisitions, and market development in the UK, Europe and the US. He will join the Nomination Committee.
Richard Cotton, a Chartered Management Accountant, has been appointed Group Finance Director of Consort Medical with effect from 25 June 2012. From 2008 to 2011 he was Group Finance Director of Vitec Group plc, from 2005 to 2008 Group Finance Director at Wagon plc (Wagon plc entered administration on 10th December 2008), and from 2001 to 2005 Group Finance Director of McLeod Russell plc.
Dr Peter Fellner, Chairman of Consort Medical, said:
“The Board would like to thank Chris, Jim and Toby for their valuable contributions during their tenures as Directors of the Company, and wish them well for the future.
“We warmly welcome the appointment of Steve, Ian and Richard to the Board. They all bring substantial and wide ranging experience and we look forward to working with them as we grow Consort for the benefit of our stakeholders.
Consort confirms that there are no further disclosures to be made under Rule 9.6.13 of the Listing Rules.
Consort Medical plc – Tel: +44 (0) 1442 867920
Jonathan Glenn, Chief Executive Officer
Toby Woolrych, Group Finance Director
Brunswick Group LLP – Tel: +44 (0) 20 7404 5959
Jon Coles/Justine McIlroy/Amie Gramlick
Consort Medical plc is a leader in medical devices for inhaled drug delivery, self-injection and anaesthesia. The Group develops drug delivery systems for the pharmaceutical industry and disposable airway management products for critical care settings in hospitals.
Consort Medical’s Bespak division develops and manufactures drug delivery devices and diagnostic disposable devices, including metered dose inhaler valves, actuators, compliance aids, dry powder devices, and autoinjectors. The King Systems division develops and manufactures disposable devices for anaesthetists and emergency medical practitioners, including video laryngoscopes, disposable facemasks, breathing circuits and laryngeal tubes. The Group has facilities in Kings Lynn, Cambridge, Nelson and Hemel Hempstead in the UK, and Indianapolis, Indiana and Kent, Ohio in the US. Consort Medical is a public company quoted on the full list of the London Stock Exchange (LSE: CSRT).